Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR): a Pilot, Randomized Placebo-controlled Trial

NCT07036003 is registered in ClinicalTrials.gov with Dr. David Wasserstein as lead sponsor.

NCT NCT07036003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07036003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR): a Pilot, Randomized Placebo-controlled Trial
Lead sponsor
Dr. David Wasserstein
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 31, 2025
Completion date
January 31, 2029
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

knee osteoarthritis (knee oa), knee osteoarthritis (oa)